Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 71335-2982

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71335-2982). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Lbl713352982)

Label (Lbl713352982)
This text is an insert for a medication called Rizatriptan Benzoate Orally Disintegrating Tablets, USP. Each tablet contains 14.53 mg of Rizatriptan Benzoate USP, which is equivalent to 10 mg of Rizatriptan. It also mentions that the tablets contain phenylalanine, a component of aspartame. The usual adult dosage instructions are found in the Package Insert QR Code. The storage conditions are specified as 20° to 25°C (68° to 77°F). Additionally, it advises keeping the medication out of reach of children. The tablets come in a pack of 9 and are repackaged by Bryant Ranch Prepack, Inc. and manufactured by Aurobindo Pharma.*
FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
This description provides data from pooled studies illustrating the estimated probability of achieving an initial headache response within 2 hours of treatment with rizatriptan benzoate or a placebo. The Kaplan-Meier plot in Figure 1 shows the trend over time of obtaining headache relief (no or mild pain) based on data from 4 outpatient studies (Studies 1, 2, 3, and 4). Patients who required additional treatment or did not achieve headache relief within 2 hours were censored in the analysis.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)
The provided text discusses the estimated probability of patients taking a second dose of Rizatriptan Benzoate Tablets or other medication for migraines over the 24 hours following the initial dose of study treatment in pooled Studies 1, 2, 3, and 4. The data is presented in a Kaplan-Meier plot based on four placebo-controlled outpatient clinical trials, where patients not using additional treatments were censored at 24 hours. This plot includes patients who had a headache response at 2 hours and those who did not respond to the initial dose. Remedication was not allowed within 2 hours post-dose. The information provides insights into patient behavior regarding taking a second dose of medication for migraines.*
FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)
The text provides information about the estimated probability of achieving an initial headache response with Rizatriptan Benzoate Orally Disintegrating Tablets in Pooled Studies 5 and 6. It includes a graph showing the Kaplan-Meier plot of the probability over time of obtaining headache response following treatment with Rizatriptan Benzoate orally disintegrating tablets or placebo. The data is based on pooled data from two placebo-controlled outpatient trials (Studies 5 and 6) providing evidence of efficacy. Patients who did not achieve headache response prior to 2 hours are also mentioned in the text.*
FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)
This text provides a figure showing the observed percentage of patients reporting no headache pain by 2 hours post-dose in Study 7. The comparison is between Rizatriptan Benzoate ODT Tablets and a Placebo. The graph displays the data up to 20 hours post-stage 2 dose, with the highest percentage on Rizatriptan Benzoate ODT Tablets.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.